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Abstract 
Background: The development and spread of chloroquine-resistant Plasmodium falciparum threatens the health of 
millions of people and poses a major challenge to the control of malaria. Monitoring drug efficacy in 2-year intervals is 
an important tool for establishing rational anti-malarial drug policies. This study addresses the therapeutic efficacy of 
artemether-lumefantrine (AL) for the treatment of Plasmodium falciparum in southwestern Ethiopia.
Methods: A 28-day in vivo therapeutic efficacy study was conducted from September to December, 2011, in south-
western Ethiopia. Participants were selected for the study if they were older than 6 months, weighed more than 5 kg, 
symptomatic, and had microscopically confirmed, uncomplicated P. falciparum. All 93 eligible patients were treated 
with AL and followed for 28 days. For each patient, recurrence of parasitaemia, the clinical condition, and the presence 
of gametoytes were assessed on each visit during the follow-up period. PCR was conducted to differentiate re-infec-
tion from recrudescence.
Results: Seventy-four (83.1 %) of the study subjects cleared fever by day 1, but five (5.6 %) had fever at day 2. All 
study subjects cleared fever by day 3. Seventy-nine (88.8 %) of the study subjects cleared the parasite by day 1, seven 
(7.9 %) were blood-smear positive by day 1, and three (3.4 %) were positive by day 2. In five patients (5.6 %), para-
sitaemia reappeared during the 28-day follow-up period. From these five, one (1.1 %) was a late clinical failure, and 
four (4.5 %) were a late parasitological failure. On the day of recurrent parasitaemia, the level of chloroquine/desethyl-
chloroquine (CQ-DCQ) was above the minimum effective concentration (>100 ng/ml) in one patient. There were 84 
(94.4 %) adequate clinical and parasitological responses. The 28-day, PCR-uncorrected (unadjusted by genotyping) 
cure rate was 84 (94.4 %), whereas the 28-day, PCR-corrected cure rate was 87 (97.8 %). Of the three re-infections, 
two (2.2 %) were due to P. falciparum and one (1.1 %) was due to P. vivax. From 89 study subjects, 12 (13.5 %) carried P. 
falciparum gametocytes at day 0, whereas the 28-day gametocyte carriage rate was 2 (2.2 %).
Conclusions: Years after the introduction of AL in Ethiopia, the finding of this study is that AL has been highly effec-
tive in the treatment of uncomplicated P. falciparum malaria and reducing gametocyte carriage in southwestern 
Ethiopia.
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Background
Although there have been encouraging reports of declin-
ing of morbidity and mortality from malaria in most 
endemic countries [1], it remains an overwhelming pub-
lic health problem. At present, approximately 198 mil-
lion people have malaria worldwide, leading to 5,84,000 
deaths per year. Ninety percent of these deaths are in 
Africa, and approximately 453,000 of those are children 
under five children [2].
In Ethiopia 75 % of the area is malarious, and approxi-
mately 52 million people live in high-risk areas, mainly 
at altitudes below 2,000 metres [3]. Plasmodium falcipa-
rum and P. vivax are the two dominant parasite species, 
with relative frequencies of about 60 and 40  %, respec-
tively (although thosevary by location and season). Still, 
Plasmodium falciparum is the dominant parasite species, 
causing severe and complicated manifestations and is 
responsible for most malarial deaths [4].
Early diagnosis and effective treatment are essential 
elements for the control of malaria. However, one of the 
obstacles to controlling malaria is the capability of the 
parasites to evolve resistance to various anti-malarial 
drugs. Plasmodium falciparum has an extraordinary abil-
ity to do this, creating a major challenge for the control 
efforts and increasing the number of deaths in sub-Saha-
ran Africa [5, 6].
In Ethiopia, resistance of P. falciparum to a standard 
triple-dose of chloroquine (25  mg base/kg) [7], and a 
report from Debre Zeit of chloroquine (CQ) treatment 
failure for P. falciparum and P. vivax, brought a policy 
change, and sulfadoxine-pyrimetamine (SP) has been 
used as an affordable alternative treatment of uncompli-
cated malaria cases since 1998 [8]. Unfortunately, unlike 
chloroquine, SP was used extensively, and parasites 
developed resistance within a short time [9]. Moreo-
ver, earlier studies reported widespread and high rates 
of therapeutic failure to SP for the treatment of P. falci-
parum [10]. As a result, in 2001, WHO recommended a 
shift to artemisinin-based combination therapy (ACT) 
for the treatment of P. falciparum malaria for all coun-
tries experiencing resistance to monotherapies in 2001 
[11]. Accordingly, Ethiopia replaced SP by artemether–
lumefantrine (AL), which showed no treatment failure 
and no significant after a follow-up period of 14 days in 
2004 [12]. Replacing ineffective anti-malarial drugs with 
ACT has reduced the morbidity and mortality associated 
with malaria. SP is still used, however, as intermittent 
preventive therapy for pregnant women in Ethiopia [13].
ACT was designed to attack malaria parasites with dif-
ferent mechanisms of action simultaneously. It reduces 
the emergence of drug resistance, and it gives a faster 
relief from clinical symptoms and parasite clearance [14]. 
Artemether is quickly hydrolyzed to dihydroartemisinin 
(DHA), its main active metabolite, and absorbed rap-
idly. Artemether and DHA reduce asexual parasite mass 
by 10,000-fold per reproductive cycle. The partner drug, 
lumefantrine, is absorbed and cleared more slowly, act-
ing to eliminate the remaining parasites and thus prevent 
recrudescence [15]. Twice-daily dosing of AL for 3 days 
maintains artemether and DHA concentrations at supra-
therapeutic levels [16].
To insure timely changes to treatment policy, WHO 
recommended therapeutic efficacy studies of the drug 
every 2  years [5]. Accordingly, a study of AL was con-
ducted in Kersa, and it reported excellent therapeutic 
efficacy [17]. However, in 2006 reports of higher recru-
descence rates of P. falciparum malaria after treatment 
with ACTs emerged from observational data collected 
in Cambodia [18]. Moreover, another study carried out 
in 2006 and 2007 in Battambang province, Cambodia, 
showed delayed parasite clearance times [19]. Delay in 
parasite clearance and subsequent treatment failure is 
multifactorial in origin, with the host, parasite, and drug 
factors contributing almost equally. As a consequence, 
there has been an increasing concern about the delay in 
parasite clearance with artemesinin in Southeast Asia 
Since 2009 [20].
The development of resistance to ACT could have a 
major impact on malaria control efforts at time when 
there are no other drugs in the development pipeline. 
Therefore, the primary aim of this study was to assess the 
therapeutic efficacy of AL for the treatment of uncom-
plicated P. falciparum malaria in Southwestern Ethiopia. 
The secondary objectives of the study were to determine 
the prevalence of post-treatment gametocyte carriage 
in Southwestern Ethiopia. This information will inform 
policy makers with respect to appropriate antimalarial 
strategies.
Methods
This study was conducted between August and Decem-
ber (the malaria season), 2001, at Omo Nada health 
center in southwestern Ethiopia. Following WHO pro-
tocols [21], we evaluated the clinical and parasitological 
responses to the treatment of uncomplicated P. falcipa-
rum malaria with artemether–lumefantrine (Fig. 1).
Study area, period and design
Omo Nada (7°37′60″N, 37°15′0″E) is one of the wore-
das (the name for districts in Ethiopia) in Jimma Zone, 
Oromia Region of Ethiopia. Nada is the administrative 
center of the woreda; other towns in Omo Nada include 
Asendabo. The altitude of this woreda ranges from 1,000 
to 3,340 meters above sea level, and its total population is 
2,48,173. As in most other places, malaria transmission 
in Omo Nada follows rainy seasons, with transmission 
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peaking in the months between September and Decem-
ber and between April and May. The main malaria con-
trol strategy in the woreda includes use of Long Lasting 
Insecticidal Nets (LLINs), malaria case management 
with ACTs, and intermittent preventive treatment during 
pregnancy (IPTp) [22].
Sample size determination
For therapeuthic efficacy studies, sample sizes (n) were 
calculcated based on recommendations by the Techni-
cal Expert Group on Malaria Chemotherapy [21], using 
the formula n = (Z/d)2 P (1 − P), where P stands for the 
anticipated prevalence, d for the margin of error, and Z 
for the Z statistic at a given level of confidence. For the 
level of confidence of 95  %, the Z value is 1.96. In this 
study a 5 % failure rate was expected, the precision level 
was set a 4.5 %, and a loss-to-follow-up rate was antici-
pated to be 20 % over 28-days. Thus the calculated sample 
size was 93, which was considered sufficient to address 
the study objectives.
Study subjects and inclusion criteria
The study subjects were recruited among P. falciparum-
positive patients visiting health centres who met the 
WHO inclusion guidelines for the assessment and moni-
toring of anti-malarial drug efficacy for the treatment of 
uncomplicated malaria [5]. The details of inclusion and 
exclusion criteria are presented as follows:
The inclusion criteria were as follows:
  • Over 6 months of age
  • Living in areas of low-to-moderate transmission
  • Mono-infection with P. falciparum detected by 
microscopy
  • Asexual parasite count of 1,000–100,000/µl in areas 
of low-to-moderate transmission
  • Axillary temperature  ≥37.5  °C or history of fever 
during the 24 h before recruitment
  • Ability to swallow oral medication
  • Ability and willingness to comply with the protocol 
for the duration of the study and to comply with the 
study visit schedule
  • Informed consent from the patient (or parent or 
guardian in the case of children, and assent from 
children between 7 and 17 years)
The exclusion criteria were as follows:
  • General danger signs in children under 5  years 
(coughing or difficulty breathing) or signs of severe 
P. falciparum malaria, according to the definitions of 
WHO
Fig. 1 Study subjects participated on AL efficacy study and treatment outcome. From a total of 125 P. falciparum cases, 93 fulfilled the inclusion 
criteria and gave written and informed consent and assent to participate in the therapeutic efficacy of AL for the treatment of P. falciparum, while 
32 study subjects did not meet the inclusion criteria and were excluded from the study. From 32 excluded from the study, 11 excluded to provide 
consent and assent, 12 had a low parasite count from the thick blood film, 2 had sever disease (Tb positive) and 7 were less than 6 months. Among 
the 93 study participants, one blood film reading was discrepant between the two microscopic readers and decision was made based on the third 
senior laboratory personnel reading. On the first day of the study, two study subjects vomited the drug twice and excluded from the study and 
analysis. On day 14 and 21, two patients did not return on the follow-up day. We could not find one of the patients, and we were informed that the 
other patient had moved from the area, so both were considered lost to follow-up.
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  • Severe malnutrition according to WHO growth 
standards (defined as follows: for children 6 months 
to 18  years, a growth standard z-score below −3, 
symmetrical oedema involving at least the feet or 
a mid-upper arm circumference of  <110  mm; for 
adults, a mid-upper arm circumference of <170 mm, 
BMI  <16 with or a mid-upper arm circumfer-
ence <180 mm with recent weight loss or underlying 
chronic illness).
  • Febrile condition due to diseases other than malaria 
(e.g., measles, acute lower respiratory tract infection, 
severe diarrhea with dehydration) or other known 
underlying chronic or severe diseases (e.g., cardiac, 
renal or hepatic diseases, HIV/AIDS)
  • Regular medication which might interfere with anti-
malarial pharmacokinetics (like antiretroviral drugs)
  • History of hypersensitivity reactions to any medicine 
tested or used as an alternative treatment or con-
traindication to AL
  • Pregnant or breastfeeding women
Blood film management during each follow up days
Thick and thin blood smears were prepared and stained 
with 10  % Giemsa for 10  min. The stained blood films 
were examined on days 0, 1, 2, 3, 7, 14, 21, and 28, as 
well as on any unexpected visits with the patient due to 
the patient suffering a malaria attack before the day of 
the next appointment. Two laboratory personnel read 
the blood film slide independently. Blood smears with 
discordant results (differences between the two micros-
copists in species diagnosis, or differences in parasite 
density of >50 %) were re-examined by a third, independ-
ent microscopist, and parasite density was calculated by 
averaging the two closest counts. A blood film was con-
sidered negative when no parasite was found after exam-
ining 100 fields. On day 0, hemoglobin was determined 
for those study subjects who were willing to participate 
on the study. Parasite count was based on the number of 
asexual parasites observed against 200 leukocytes. This 
number was then multiplied by 40 to gain an approxi-
mate count per microlitre.
Parasite densities for all participants were calculated 
using an assumed WBC of 8.0 × 10(9)/L of blood, which 
has been set by WHO to be used for convenience in facil-
ities which lack the tools to determine patients’ absolute 
full blood cell count (FBC) values. In addition, the whole 
Giemsa-stained thick film was examined for gametocyte 
carriage before and after artemether–lumefantrine treat-
ment on all follow up days.
No. parasites per/µL
= Parasite count × 8,000/200WBC
Treatment of Plasmodium falciparum with AL and follow‑up
As a routine procedure within the health system of 
Ethiopia, study subjects were treated with AL (Arte-
fan) (Ajanta pharma limited, Charkop, Kandivli (W), 
Mumbai 400 067, India) twice daily on days 0, 1, and 2. 
Study medication was administered based on weight; 
the first dose were administered under the supervi-
sion of a qualified member of the study staff. Study 
subjects were followed for 30 min post treatment as an 
additional procedure from the routine ones. If vomit-
ing occurred, a second full dose was administered. If 
repeated vomiting occurred, patients were withdrawn 
from the study and offered rescue therapy. Patients 
who failed to respond to AL treatment during the 
28  days of follow-up were treated with oral quinine 
(8 mg/kg per day for 7 days), which is a second line of 
drugs and a regular treatment regime for the treatment 
of malaria in Ethiopia.
Patients were asked to return to the health centre on 
days 1, 2, 3, 7, 14, 21, 28 or if suffering from a malaria 
attack before the day of the next appointment. On each 
follow-up day, blood was examined for the presence or 
absence of parasites, and temperature was measured. 
Those patients with recurrence of parasites during the 
follow-up days were treated with quinine. Patients were 
considered lost to follow-up when they did not come to 
the clinic as scheduled and became unreachable.
DNA extraction and molecular detection
DNA was isolated using QIAgen DNA Mini Kit for blood 
and tissue (QIAGEN, Germany), based on the manu-
facturer’s instructions, and stored at −20  °C until use. 
A nested PCR assay was then carried out as previously 
described elsewhere [23].
The most widely used genetic markers for malaria 
genotyping—the antigen genes msp1, msp2 and glurp—
were used in this here; these markers have been shown 
to have adequate discriminatory power for recrudes-
cence versus re-infection testing [24]. Merozoite sur-
face protein 1 (msp1) alleles of P. falciparum can be 
divided into 17 distinct blocks. Exept block 2 region, 
the non-conserved sequences can be grouped into 
major families represented by the MAD20 [25]. Allelic 
polymorphism in block 2 was widespread with over 
50 different variants. However, these sequences fall 
into three main types represented by K1, MAD20, and 
RO33 isolates [26]. The msp2 alleles are grouped into 
two allelic families, FC27 and 3D7/IC1. Msp2 is highly 
polymorphic because of intragenic repeats [5, 27]. All 
the primer sequences were adopted from the World-
wide Antimalarial Resistance Network WWARN (2005) 
(Table 1) [5].
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Study endpoints
Treatment outcomes for AL were determined based on 
the WHO classification of treatment outcomes as follows: 
(1) early treatment failure (ETF), (2) late clinical failure 
(LCF), (3) late parasitological failure (LPF), and (4) ade-
quate clinical and parasitological response (ACPR) [21].
Ethical clearance
Ethical clearances were obtained from Aklilu Lemma 
Institute of Pathobiology (ALIPB), Armauer Hansen 
Research Institute (AHRI/ALERT) and Jimma Univer-
sity before commencing the projects. The Investigator 
explained the study to each potential subject verbally, 
provided all the information (purpose, procedures, risks, 
benefits, alternatives to participation, etc.), and gave time 
for any queries. Then the potential subject was provided 
with a written consent form and afforded sufficient time 
to read it. Once an individual had all his/her questions 
answered and agreed to participate in the study, they 
or their family or guardian signed an informed consent 
prior to inclusion in the study. Confidentiality of infor-
mation and freedom to withdraw from the study anytime 
were guaranteed. In addition, study subjects were com-
pensated for transportation costs during the 28-day fol-
low-up period.
Results
Study subject participated on AL efficacy study
Among 150 P. falciparum-positive patients visiting 
Omo Nada health centers, 93 fulfilled the inclusion 
criteria and were included on the AL efficacy study. Of 
these, two vomited twice within 30 min, and two were 
lost to follow-up; thus these were excluded from the 
study.
Patient characteristics
The majority of the study subjects (59.8  %) were male. 
The mean age and temperature of the study subjects were 
17.3  years and 37.7  °C, respectively. The minimum hae-
moglobin level was 8.0  g/ml, while the maximum hae-
moglobin level was 14.6  g/ml. The mean parasite load 
counted from the thick blood film was 8,404 (2,960–
18,400) (Table 2).
Fever and parasite clearance
Seventy-four (83.1 %) of the study subjects cleared fever 
by day 1, ten (11.2  %) still had fever on day 1, and five 
(5.6 %) had fever on day 2. All study subjects cleared fever 
by day 3. In addition, 79 (88.8  %) of the study subjects 
cleared the parasite by day 1, seven (7.9 %) were blood-
smear positive by day 1, and three (3.4 %) were positive 
by day 2 (Table 3).
Treatment outcome during the 28‑day follow‑up period
Among 89 patients who were included in this study, five 
(5.6 %) were classified as treatment failures. One (1.1 %) 
was a late clinical failure, and four (4.5  %) were late 
parasitological failures. From the four late parasitologi-
cal failures, parasites were identified from three study 
subjects on day 14 and from one study subjects on day 
21. There were 84 (94.4  %) adequate clinical and para-
sitological responses. PCR uncorrected cure rate (unad-
justed by genotyping) was 94.4 % (95 % CI 88.0–97.9 %) 
and the PCR corrected cure rate was 97.8  % (95  % CI 
Table 1 Specific primers for msp1 and msp2 primer sets
All the primer sequences were adopted from Worldwide Antimalarial Resistance Network, WWARN (2005).
Locus Allele Primer Sequence (5′ to 3′) 
Forward Reverse
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92.8–99.6  %). Of the three re-infections, two (2.2  %) 
were due to P. falciparum and one (1.1 %) was due to P. 
vivax (Table 4).
There were 33 study subjects ≤5 years of age and the 
rest (56) were above 5  years of age. In  ≤5  years of age 
the PCR-uncorrected cure rate was 97.0  % (95  % CI 
86.0–100.0 %) while PCR-corrected cure rate was 100.0 % 
(95  % CI 91.3–0.0  %). On the other hand, PCR-uncor-
rected and corrected cure rates in study subjects above 
5  years of age were 92.9  % (95  % CI 83.7–97.7  %) and 
96.4 % (95 % CI 88.7–99.4 %) respectively (Table 5).
Gametocyte determination using microscopy
The whole thick blood films were examined for the 
presence of gametocyte stages. From 89 study subjects, 
12 (13.5  %) carried P. falciparum gametocytes at day 0, 
whereas the 28  days gametocyte carriage rate was 2 
(2.2 %) (Table 3).
Discussion
The remarkable ability of P. falciparum to evolve resist-
ance to a number of anti-malarial drugs has recently 
increased the number of deaths from malaria worldwide 
[6, 28]. Chloroquine-resistant P. falciparum [7] and high 
rates of failure to SP [10, 29] have been some of the chal-
lenges to combatting malaria in Ethiopia. In response, 
Artemether–lumefantrine (AL), one of the artemesinin 
combination therapy (ACT) regimens recommended as 
first line drug by the World Health Organization in 2001, 
has been used and proved efficacious for the treatment of 
uncomplicated P. falciparum malaria since 2004 in south-
western Ethiopia. All 93 P. falciparum mono-infections in 
our study received AL, and 74 of them (83.1 %) resolved 
their fever by day 3. AL is known to clear fevers in a very 
short period of time (less than 3 days). The parasite clear-
ance in this study was faster than the result reported 
from Thai–Cambodian border where the parasite resist-
ance was characterized in this efficacy study [30].
Unfortunately, the description of artemisinin resistance 
in Southeast Asia [20] and the China–Myanmar border 
[31] is a global concern. Failure to rapidly clear parasites 
will compromise the use of artemisinin for the treatment 
of severe malaria. Slow parasite clearance in patients 
treated with an ACT causes more parasites to be exposed 
to the partner medicine alone, increasing the risk of resist-
ance developing to the partner medicine. If this occurs, 
Table 2 Baseline characteristics of study subjects involved 
in AL the efficacy study
Patient characteristics Value
Gender (M %/F %) 59.8 %/40.2 %
Mean age (Year) 17.3 (1–60)
Mean temperature, axillary (°C) 38.8 °C  
(37.5–40.0 °C)
Mean hemoglobin (gm/ml) 11.6 g/ml  
(8.0–40.0 gm/ml)
Parasite load (µl) 8,404 (2,960–18,400)
Weight (kg) 34.4 kg (6–69 kg)
Table 3 Patient recruitment and follow up for 28 days
Characteristics n
Fever clearance
 Fever present on day 1 10 (11.2)
 Fever present on day 2 5 (5.6)
 Fever present on day 3 0 (0.0)
Parasite clearance
 Smear positive on day 1 7 (7.9)
 Smear positive on day 2 3 (3.4)
 Smear positive on day 3 0 (0.0)
Appearance of gametocytes
 Gametocyte carriage on day 0 12 (13.5)
 Gametocyte carriage on day 28 2 (2.2)
Table 4 Treatment outcome during  28  days follow 
up period
Treatment outcome N (%)
Treatment failure
 Late clinical failure 1 (1.1)
 Late parasitological failure 4 (4.5)
Adequate clinical and parasitological response 84 (94.4)
 28 days PCR uncorrected cure rate 84 (94.4)
 28 days PCR corrected cure rate 87 (97.8)
Re-infection
 Recurrent malaria by P. vivax 1 (1.1)
 Recurrent malaria by P. falciparum 2 (2.2)
Recrudescence 2 (2.2)
Table 5 Treatment outcome during  28  days follow 
up period in different age group






LCF 0 1 (1.8) 1 (1.1)
LPF 1 (3.0) 3 (5.4) 4 (4.5)
ACPR 32 (97.0) 52 (92.9) 84 (94.4)
28 days PCR uncorrected 
cure rate
32 (97.0) 52 (92.9) 84 (94.4)
28 days PCR corrected 
cure rate
33 (100.0) 54 (96.4)) 87 (97.8)
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treatment failures are likely to increase [32]. Among the 
five treatment failures, one (1.1 %) was a late clinical fail-
ure and four (4.5  %) were late parasitological failures. 
From the four late parasitological failures, parasites were 
identified from three study subjects on day 14 and from 
one study subjects on day 21. All the four late parasito-
logical failures were treated with quinine, the standard 
second-line drug for the treatment of falciparum malaria 
in Ethiopia. In the current study there were 84 (94.4  %) 
adequate clinical and parasitological responses. That 
means PCR uncorrected cure rate (unadjusted by geno-
typing) was 94.4  % (95  % CI 88.0–97.9  %) and The PCR 
corrected cure rate was 97.8 % (95 % CI 92.8–99.6 %). It 
is concluded that the efficacy of AL for the treatment of 
uncomplicated falciparum malaria was high in this study.
Likewise, the high efficacy of AL has been reported 
in earlier studies from Ethiopia [33–35]. Another study 
from southern Ethiopia reported a 97.2 % cure rate and 
showed that the drug could continue as a first-line treat-
ment [36]. Moreover, high efficacy of AL in the treat-
ment of uncomplicated malaria was confirmed by Seboxa 
et  al. [5] in their study from southwestern Ethiopia and 
the finding of this study is in agreement with reports of 
high efficacy of AL in East African countries [37, 38]. 
The reason for the efficacy of AL was its rapid killing of 
the sexual stages of P. falciparum and the activity of AL 
on gametocytes. Modeling studies have suggested that 
the spread of anti-malarial drug resistance is primar-
ily driven by a “window of selection” after therapy, and 
the duration of this window is increased for drugs with 
longer elimination half-lives. The artemisinin drugs have 
short elimination half-lives and are thus less likely to 
select for resistance [39, 40]. Moreover, in the Ethiopian 
context, the distribution of AL only in the government 
sectors (organizations) has minimized the distribution 
of counterfeit drugs, which have already penetrated the 
African market [41]. In Cambodia, the epicentre for anti-
malarial drug resistance, the cheaper “artesunate” con-
tains 6 % chloroquine but no artesunate, and the cheaper 
“mefloquine” contains sulfadoxine-pyrimethamine but 
no mefloquine. Chloroquine and sulfadoxine-pyrimeth-
amine are ineffective in this area [42].
In the current study the whole thick blood films were 
examined for the presence of the gametocyte stage, and 
there was a signifiant reduction of gametocyte carriage 
at day 28. Gametocyte carriage reduction after treat-
ment was also seen in children with uncomplicated P. 
falciparum malaria in southwestern Nigeria: fter treat-
ment with AL, 8, 1, 1, 3, 3, and 3 children were gameto-
cyte carriers on days 0, 3, 7, 14, 21, and 28, respectively 
[43]. In addition, a study in Thailand showed that when 
artemisinin derivatives were introduced as a compo-
nent of first-line treatment, there was a significant 
reduction in the incidence of clinical P. falciparum 
malaria during the next 2 years [44]. Furthermore, arte-
misinin is active against the broadest range of stages in 
the life cycle of Plasmodium species and kills gameto-
cytes, the sexual stage of the malaria parasite respon-
sible for infection of the mosquito. Artemisinins also 
kill immature and developing gametocytes, the sex-
ual stages that are essential for transmission, thereby 
reducing transmission and contributing to malaria-
control programs [45].
One of the limitations of this study was AL was given 
without fatty food. As well known, food enhances the oral 
absorption of artemether and lumefantrine. In healthy 
volunteers, the relative bioavailability of artemether 
increased by two- to threefold and that of lumefantrine 
by 16-fold when administered after a high-fat meal, as 
opposed to under fasting conditions [46].
Conclusions
Eight years after the introduction of AL, this efficacy 
study revealed that it has been highly effective in the 
treatment of uncomplicated P. falciparum malaria and 
reducing gametocyte carriage in southwest Ethiopia. The 
result of this study supports the continuation of AL as a 
first line treatment for uncomplicated malaria, and there 
is presently no threat of artemisinin resistance develop-
ing in Southwest Ethiopia. This result can perhaps be 
generalized to areas with similar setting in East Africa.
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